SCHEMBL5451428

SCHEMBL5451428

CN1CCc2cc(N(C)C)c(S(=O)(=O)c3ccc(Cc4cccc(C(F)(F)F)c4)cc3)cc2CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GALR3 O60755 1/20 0.42
KDM4E B2RXH2 2/20 0.39
RORC P51449 1/20 0.38
HTR6 P50406 1/20 0.37
LMNA P02545 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
ALDH1A1 P00352 2/20 0.37
GPR52 Q9Y2T5 1/20 0.37
GAA P10253 1/20 0.37
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
TSHR P16473 1/20 0.36
HTT P42858 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
CARM1 Q86X55 2/20 0.36
PRMT6 Q96LA8 2/20 0.36
USP2 O75604 1/20 0.36
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3323926 0.88 GPR52 (0.37) GALR3HTR6SMN1; SMN2GPR52HTR2A
SCHEMBL5466786 0.87 SIGMAR1 (0.42) RORCHTR6SMN1; SMN2ALDH1A1KMT2A
SCHEMBL14411990 0.87 HTR6 (0.43) HTR6SMN1; SMN2HTR2AHTR2CUSP2
SCHEMBL5455402 0.86 HRH3 (0.38) RORCHTR6LMNASMN1; SMN2ALDH1A1
SCHEMBL5457191 0.86 CARM1 (0.38) GPR52HTR2ACARM1PRMT6
SCHEMBL5458151 0.85 LTA4H (0.43) KDM4ERORCHTR6LMNASMN1; SMN2
SCHEMBL5462496 0.85 KCNH2 (0.38) RORCHTR6SMN1; SMN2HTR2AHTR2C
SCHEMBL5467092 0.85 HTR2A (0.37) HTR6HTR2AHTR2CCA1CA2
SCHEMBL5453931 0.85 USP2 (0.36) HTR6SMN1; SMN2HTR2AHTR2CUSP2
SCHEMBL5459290 0.85 USP2 (0.36) HTR6SMN1; SMN2GPR52HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents GLAXO GROUP LIMITED (GB) 2007-09-27 US claimed
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents GLAXO GROUP LIMITED (GB) 2007-09-27 US disclosed
EP-1687005-A1 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2006-08-09 EP disclosed
WO-2005051398-A1 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents HTR4, DRD4, SLC6A3 GALR3 238/4885KDM4E 418/4885RORC 1630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.